AmberGen

AmberGen is a company at the forefront of spatial biology research, providing a suite of products under the Miralys brand, including probes, panels, and kits. These products are centered around the patented Miralys Photocleavable Mass-Tag Imaging technology, which significantly enhances mass spectrometry imaging capabilities by allowing the imaging of over 150 intact protein biomarkers in just 45 minutes. AmberGen’s technology facilitates multiomic imaging of small molecules, lipids, glycans, extracellular matrix, and intact proteins on the same panel. Additionally, the company offers dual-labeled antibody probes that merge mass-tags with fluorophores for multimodal imaging, as well as Miralys Antibody Conjugation kits for custom labeling of antibodies with photocleavable mass-tag codes. In collaboration with Bruker, AmberGen develops spatial biology imaging reagents for MALDI-Immunohistochemistry (MALDI-IHC). In 2022, AmberGen received a minority investment from Bruker Corporation, underscoring its innovative contributions to the field of spatial biology.